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Abstract
Background: A functional interferon regulatory element (IRE) has been found in the EnhI/X promoter region of
hepatitis B virus (HBV) genome. The purpose of this study is to compare the gene order of responder and non-
responder to interferon therapy in patients with chronic hepatitis B (CHB), so as to evaluate the relationship
between IRE mutation and the response to interferon treatment for CHB patients.
Results: Synthetic therapeutic effect is divided into complete response (CR), partial response (PR) and non-
response (NR). Among the 62 cases included in this study, 40 cases (64.5%) were in the response group (CR and
PR) and 22 (35.5%) cases were in the NR group. Wild type sequence of HBV IRE TTTCACTTTC were found in 35
cases (56.5%), and five different IRE gene sequences. included TTTtACTTTC, TTTCAtTTTC, TTTtAtTTTC, TTTtACTTTt
and cTTtACcTTC, were found in 22 cases (35.5%), 1 case (1.6%), 1 case (1.6%), 2 cases (3.2%) and 1 case (1.6%)
respectively. There were 41.9%cases (26/62) with forth base C®T mutation, consisted of 32.5% (13/40) cases in
response group and 59.1% (13/22) cases in NR group. Among the 35 cases with IRE sequences, there were 67.5%
(27/40) cases in response group and 36.4% (8/22) in NR group, and the difference in IRE sequences between two
groups was statistic significantly (P = 0.027). The result suggested that there is likely relationship between the forth
base mutation (C®T) of IRE region and the response of HBV to Interferon therapy, and this mutation may partially
decrease the inhibition effect of interferon on HBV.
Conclusion: The forth base C®T mutation in IRE element of HBV may partially influence the response of
Interferon treatment in CHB patients.
Background
Hepatitis B virus (HBV) infection is a serious global
health problem, with 2 billion people infected world-
wide, and 350 million suffering from chronic HBV infec-
tion [1]. It’s estimated that over 1 million HBV infected
patients died annually because of hepatic decompensa-
tion, cirrhosis and hepatocellular carcinoma (HCC)[2,3].
Evidence showed that antiviral treatment is the only way
to reduce morbidity and mortality from chronic HBV
infection.
Currently, antiviral treatments for chronic hepatitis B
( C H B )i n c l u d ei n t e r f e r o n( I F N )t h e r a p ya n dn u c l e o -
side analogues [4]. Because of anti-HBV and
immunoregulation dual functions [5-11], IFN has been
widely used in past decade. However, existing clinical
data suggested that the anti-viral effect of IFN is not
satisfactory at present; for patients with active liver
inflammatory, the efficiency of IFN is only about 30%-
50% in clinical observation, and 50%-70% patients had
no response. As one of the main anti-HBV drugs, the
action site and mechanism of interferon are not comple-
tely clear. Evidence shows that the inhibition of virus
replication by IFN needs that the cell can activate anti-
virus effect, and also the virus is sensitive to the action.
As the sensitivities of different HBV strains (like the dif-
ferent genotype or some district of the gene variations)
to the interferon are different [12,13]. Therefore, the
anti-HBV effect of interferon is affected by the factors
of both host and virus.
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replication by interferon may influence both transcrip-
tional and post-transcriptional regulation [14,15]. The
antiviral effect of interferon is through the activation of
JAK-STAT signal transduction pathways. Interferon
induces the formation of a heterotrimetric transcription
factor complex, interferon-stimulated gene factor 3
(ISGF3), which consists of signal transducers and activa-
tors of transcription 1 and 2 (STAT1 and STAT2) and
interferon regulate factor 9(IRF9), after binding to its
receptor. ISGF3 translocates into the nucleus, binds to
the interferon-stimulated regulatory element (ISRE) and
transactivates the expression of Interferon stimulated
genes (ISG) such as the Interferon regulatory factor 7
(IRF7), the Interferon regulatory factor 1 (IRF1) and the
Interferon regulatory factor 2 (IRF2) etc. There is a
functional interferon regulatory element (IRE) in HBV
enhancerI/X promoter region [16], which can mediated
the regulation of gene transcription by IFN a, the Inter-
feron-stimulated 3 (ISGF3), the Interferon regulatory
factor 1 (IRF1) and the Interferon regulatory factor 7
(IRF7)[17]. It was suggested that interferon probably
regulates HBV gene transcription directly through the
IRE sequence. However, the role of IRE in the effect of
interferon in CHB treatment is still not clear. In this
study, the sequences of IRE region of HBV from respon-
der and non- responder to interferon therapy in patients
with CHB were compared, and the relationship between
IRE mutation and the response to interferon were
analyzed.
Results
General information
Among those 62 patients, thirty four males and six
females were in the response group, aged from 3 to 51
years (28.9 ± 11.0 years), and seventeen males and five
females were in the non-response group, aged from 16
to 45 years (28.0 ± 8.3 years). Fifty-three patients were
positive for HBeAg and nine patients were negative for
HBeAg (Table 1).
Response to the Interferon treatment
As to serum virological response (SVR) there were 20
cases for complete response group, in which 16 cases
were positive for HBeAg while 4 cases were negative for
HBeAg. There were 18 cases for partial response group,
in which 15 cases were positive for HBeAg and 3 cases
were negative for HBeAg. There were 24 cases for non-
response group, in which 22 cases were positive for
HBeAg and 2 cases were negative for HBeAg.
As to SIR there were 16, 7 and 30 cases each for com-
plete, partial and non-response group. In addition as to
HBsAg there was one case each in HBeAg-positive and
HBeAg-negative group turned negative, with appearance
of anti-HBs in the former group and without it in the
latter group at the end of six months treatment.
There were 35 cases with ALT recovered in which 2
cases (5.7%) were in SVR non-response group, 15 cases
(42.9%) in SVR partial response group and 18 cases
(51.4%) in SVR complete response group. There were 27
cases with ALT failed to return to normal, in which 22
cases (81.5%) were in SVR non-response group, 3 cases
(11.1%) in SVR partial response group and 2 cases
(7.4%) in SVR complete response group.
Combined the results of SVR, SIR and SBR together,
the therapeutic effect evaluation results were as follow-
ing: 13 cases were as CR; 27 cases were as PR and 22
cases were as NR. Therefore 40 cases were in response
group and 22 cases were in non-response group.
Different patterns of mutation in the IRE region of HBV
As shown in Figure 1, the size of target band containing
IRE was 371 bp. Sequence analysis showed there were
six kinds of IRE sequences variants as shown in Figure
2. The wild type sequence was TTTCACTTTC accord-
ing to the sequence of 12 ayw HBV strains and 15 adr
HBV strains. Among the 62 patients, there were 35cases
(56.6%) with wild type IRE and 27 cases with variant
IRE sequences. Five different IRE variants were
TTTtACTTTC (22 cases, 35.5%), TTTCAtTTTC (1
case, 1.6%), TTTtAtTTTC (1 case, 1.6%), TTTtACTTTt
(2 cases, 3.2%) and cTTtACcTTC (1 case, 1.6%).
Comparison of HBV IRE mutation between response and
non-response group
There were 27 responders and 8 non-responders with
wild type IRE sequences TTTCACTTTC, while there
were 10 responders and 12 non-responders with mutant
IRE sequences TTTtACTTTC (Table 2).
There were 10 complete responders to interferon, 17
partial responders and 8 non-responders in the patients
whose IRE sequences were TTTCACTTTC, while there
were 3 complete responders to interferon, 7 partial
responders and 12 non-responders in the patients whose
IRE sequences were TTTtACTTTC.
Table 1 Baseline characteristics and disease status of
patients
Response Non-response
Patients, n 40 22
Age, years(mean ± SD) 28.9 ± 11.0 28.0 ± 8.3
Sex, male(no.,%) 34(85.0) 17(77.3)
Pathogenesis, days(mean ± SD) 1719.5 ± 1168.0 1503.8 ± 1322.1
Family history(no.,%) 7(17.5) 2(9.0)
HBV DNA, log copies/ml(mean ± SD) 5.1 ± 0.9 5.4 ± 1.0
ALT, IU/L(mean ± SD) 260.9 ± 84.0 248.1 ± 112.0
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base C®T mutation(2 cases, TTTC AtTTTC,
TTTtAtTTTC), tenth base C®T mutation (2 cases,
TTTtACTTTt), first base T®C mutation(1 case,
cTTtACcTTC) and seventh base T®C mutation(1 case,
cTTtACcTTC) only account for 8% of total sample.
There were 26 cases with forth base C®Tm u t a t i o n
(TTTtACTTTC 22 cases, TTTtAtTTTC 1 case,
cTTtACcTTC 2 cases, TTTtACTTTt 1 case). Among
them, 13 cases in response group and 13 cases in non-
response group. There were 35 cases with wild strain
IRE sequences (TTTCAC TTTC) which included 27
responder and 8 non-responders. According to the sta-
tistical analysis, the chi-square value was 4.869 and P
value was 0.027(P < 0.05). The results showed that the
forth base mutation (C®T) of IRE region presented
more frequent in the non-response group, suggested
that there’s likely a relationship between the forth base
mutation(C®T) of IRE region and the response to
Interferon treatment.
Methods
Patients and treatment
Sixty two serum samples of chronic hepatitis B outpati-
ents from West china hospital, Sichuan University and
People’s Hospital of Deyang City, Sichuan, China from
2004 to 2005 were included in this study. Patients eligi-
ble for the initial study had been positive for HBsAg for
more than 6 months, had elevated serum alanine amino-
transferase (ALT) levels of 2-10 times the upper limit of
normal (ULN), and had a serum HBV DNA level
≥100,000 copies/mL (≥10,000 copies/ml for HBeAg-
negative patients). Exclusion criteria were as follows:
antiviral or immunosuppressive therapy within the pre-
vious 6 months; coinfection with hepatitis C, hepatitis
D, or human immunodeficiency virus; other acquired or
inherited causes of liver disease; and preexisting cytope-
nia or decompensated liver disease.
The adult patients received subcutaneous injection of
5,000,000
u interferon-a every other day for 6 months,
and the children less than 10 years old received
Figure 1 PCR products of HBV DNA including IRE region from the serum of patients and control. M: DNA marker DL2000 A: pHBV4.1
plasmid B: pBHB 4 plasmid C: Chronic hepatitis B patient’s serum(positive control) D-F:our patient’s serums G:PAd/NS3 plasmid H: Serum of
normal person I: TE (blank control).
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u interferon-a every
other day for 6 months.
This study was approved by West China Hospital’si n s t i -
tutional review board and was conducted per the 1975
Declaration of Helsinki. All patients signed informed con-
sent forms before their inclusion in this study.
Efficacy evaluation
The serum virology responses (SVR) were divided to
complete response (decreasing of serum HBV DNA to
less than 1000 copies/ml), partial response (the decreas-
ing of HBV-DNA was more than 2 log10 IU/ml but can
still be detected) and non-response (the decreasing of
HBV-DNA was negligible).
The serum immunological responses (SIR) were
divided to complete response (loss of HBeAg and
appearance of anti-HBe in HBeAg positive patients),
partial response (loss of HBeAg without anti-HBe) and
non-response (HBeAg positive and anti-HBe negative).
The serum bio-chemical response (SBR) were divided
to complete response (decreasing of serum ALT to nor-
mal level) and non-response (the decreasing of serum
ALT was negligible).
The therapeutic effect evaluation were divided to
complete response (CR, SVR, SIR and SBR were all
complete response at the end of treatment), non-
response (NR, SVR, SIR and SBR were all non-
response) and partial response (PR, all of the rest of
mentioned). The patients were divided into response
group (including complete response and partial
response) and non-response group.
Figure 2 IRE sequences of wild strains and mutation strains. A: wild strain B: forth base point mutation(C®T) C: sixth base point mutation
(C®T) D: forth base point mutation(C®T) and sixth base point mutation(C®T) E: forth base point mutation(C®T) and tenth base point
mutation(C®T) F: first base point mutation(T®C), forth base point mutation(C®T) and seventh base point mutation(T®C).
Table 2 Comparison of HBV IRE gene sequences between
response and non-response group
HBV IRE gene sequence Response
(n = 40)
Non-response
(n = 22)
Total
(n = 62)
TTTCACTTTC 27 8 35
TTTtACTTTC 10 12 22
TTTCAtTTTC 0 1 1
TTTtAtTTTC 0 1 1
TTTtACTTTt 2 0 2
cTTtACcTTC 1 0 1
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According to AY721605 strain HBV whole genome
sequence, primers for HBV IRE sequence amplification
were designed (Sense: GCGCG GTACC GGGTA
TACAT TTAAA CCCTA; Antisense: TTAAA GCTTG
CGTCA GCAAA CA CTT GGC). And the primers
were synthesized by Invitrogen China.
After viral DNA isolation PCR was carried out to
amplify IRE sequences. Briefly the reaction was done in
a5 0μL volume. The PCR conditions were: initial heat-
ing at 94°C (5 minutes), denaturing at 94°C (45 sec-
onds), annealing at 55°C (45 seconds), and extension at
72°C (45 seconds). A total of 35 cycles were performed,
followed by a final extension at 72°C (5 minutes). The
PCR products were sequenced by Invitrogen China.
Statistical analysis
All results were expressed as median and standard
deviation (X ± s). All data were analyzed using SPSS
11.5. A chi-square test was used to determine whether
there was a difference between the groups. P-value of <
0.05 was considered statistically significant.
Discussion
The pathogenesis of CHB shows that persistent replica-
tion of HBV is closely related to the disease process. So
using effective drugs in time to inhibit HBV amplifica-
tion is very important to interrupt the disease process.
Interferon has been considered effective while treating
CHB. It was effective only in some patients, but ineffec-
tive when treating other patients. In this study, as to
SVR in the 62 patients who received standard IFN treat-
ment for six months, the complete response rate was
21.0% (13/62), partial response rate was 43.5% (27/62)
and non-response rate was 35.5% (22/62). After a six-
m o n t ht r e a t m e n t ,a st oS I Rt h er a t eo fH B e A g ,H B V
DNA and HBsAg loss was 43.4% (23/53), 30.2%(16/53),
1.9%(1/53) respectively in HBeAg positive patients. The
r a t eo fH B VD N Aa n dH B s A gl o s sw a s4 4 . 4 %( 4 / 9 ) ,
11.1% (1/9) respectively in HBeAg negative patients.
The rates in present study were higher as compared to
some other clinical studies [10], which may correlated
to the definition of therapeutic effect evaluation (com-
plete response, partial response and non-response).
Additionally, limited samples, short course of treatment
a n ds h o r tf o l l o w - u ps u r v e ya l s om a yb ec o r r e l a t e dt o
this high response rates.
Anti-HBV effect of IFN is thought to act through
JAK-STAT signaling pathway [18,19]. In this pathway
STAT1, STAT2 and IRF9 formed trimer complex called
the gene factor of the Interferon-stimulated 3 (ISGF3).
The ISGF3 combines with the Interferon- stimulated
response element (ISRE) sequence after transporting to
the cell nucleus, then activates the expression of
Interferon Stimulated Genes (ISG) such as the Inter-
feron Regulatory Factor 7 (IRF7), the Interferon Regula-
tory Factor 1 (IRF1) and the Interferon Regulatory
Factor 2 (IRF2) etc, thus inhibit viral replication and
gene expression. Therefore, the anti-HBV effects of IFN
are affected by both the host and virus. According to
current knowledge, the host factors may include the
degree of liver inflammation, the level of transaminase,
IL-12 variation during IFN therapy, the basic status of
DCs, the expression of a/b receptor of the PBMCs and
the levels of HLA-DRB1 DT before and after the ther-
apy. The virus factors include the initiation level of
HBV DNA, the decrease amplitude after one month
treatment, genotypes and the mutations of DNA [20].
Recently, several studies showed that HBV gene muta-
tion may affect IFN therapy [17,21]. A study with 48
HBeAg positive CHB patients who received IFN treat-
ment for more than 24 weeks showed that the patients
with nt1762 and nt1764 mutation had a poorer response
to IFN with lower HBV DNA decrease and HBeAg con-
version [22]. In addition the loss of HBeAg was related
not only to nt1762 and nt1764 mutation (69.5%) but
also closely to nt1896 (100%) and nt1814 mutation
(65.2%). When these mutations occurred the antiviral
efficacy of IFN was not ideal and the other antiviral stra-
tegies should be adopted. Another study showed that
the T1762-A1764 mutation of HBV DNA might affect
the clearance of the virus [20]. It suggested that virus
with T1762- A1764 mutation had strong response to
IFN therapy. IFN was not only able to clear HBV
directly but also can eliminate HBV by activating or
strengthening immune system.
It has been reported that there was a functional IRE in
HBV enhancerI/X promoter region [16], which can
mediate the regulation of gene transcription by IFN a,
gene factor of the IFN-stimulated 3, IFN regulatory fac-
tor 1 (IRF1) and IFN regulatory factor 7 (IRF7)[17]. It
s u g g e s t e dt h a tI F Np r o b a b l yr e g u l a t e dH B Vg e n et r a n -
scription directly by IRE. Therefore it is possible that
the mutation of IRE may partially block or reduce the
inhibition of IFN to HBV, causing no response occur-
ring. In this study we found that there were six kinds of
HBV IRE sequences TTTCACTTTC, TTTtACTTTC,
TTTCAtTTTC, TTTtAtTTTC, TTTtACTTTt and
cTTtACcTTC in the CHB patents included in our
study. Comparing sequence of IRE of wild strains, we
found that there were 35 cases (56.6%) among 62
patients in our study. There were five kinds of point
mutation sequences. Except for the forth base C®T
mutation, the other four kinds of point mutation,
including the sixth base C®T mutation (2 cases), the
tenth base C®T mutation (2 cases), the first base T®C
mutation(1 case) and the seventh base T®Cm u t a t i o n ( 1
case), only accounted for 8% of total sample. These
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ring during transcription.
In summary, the forth base C®T mutation in IRE ele-
ment of HBV may partially influence the response of
Interferon treatment in CHB patients. We will carry on
in vitro test in order to confirm whether the forth base
C®T mutation was specific mutation related to the
anti-HBV effect of interferon. In addition, we still collect
serum specimen of patients with no response to inter-
feron in the hope of confirm the correlation between
the HBV IRE mutation and no response to interferon
with larger sample size.
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